Hougen K, Aronsen JM, Stokke MK, Enger U, Nygård S, Andersson KB, Christensen G, Sejersted OM, Sjaastad I. Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(␣MHC-MerCreMer) mice.
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tamoxifen, regulated genes were reduced to 1/5 in the single injection group. Pronounced alteration in protein abundance and acute cardiomyopathy were observed after the four-injection protocols but not the one-injection protocol. For verification of gene inactivation following one injection of tamoxifen, this protocol was applied to MCM ϩ/0 / Serca2 fl/fl . Serca2 mRNA levels and protein abundance followed the same pattern of decline with one and four tamoxifen injections. The presence of the MCM transgene induced major alterations of gene expression while administration of tamoxifen induced additional but less gene regulation. Thus nonfloxed MCM ϩ/0 should be considered as controls for mice that carry both a floxed gene of interest and the MCM transgene. One single tamoxifen injection administered to MCM ϩ/0 /Serca2 fl/fl was sufficient for target gene inactivation, without acute cardiomyopathy, allowing acute studies subsequent to gene inactivation.
heart; MerCreMer; transgenic animal models; cardiomyopathy; gene array analysis GENETICALLY MODIFIED MOUSE models are potent tools in cardiac research. Constitutive systemic knockout of genes may be lethal in utero due to important functions of the gene of interest in other cell types than cardiomyocytes. Another confounding factor precluding analysis is that the gene of interest may play a crucial role during embryonic or postnatal cardiac development. Even in constitutive knockout models that reach adult age with a seemingly normal phenotype, compensatory changes both at the organ and cellular level might lead to misinterpretation of the functional role of genes. Moreover, for studies of gene function, it is often desirable to examine gene modifications in a tissue-or cell-specific manner.
In 2001, Sohal et al. (17) inserted a gene construct encoding a fusion protein containing two mutant estrogen-binding domains and viral Cre recombinase (MerCreMer, MCM) in the ␣-myosin heavy chain (␣-MHC) promoter construct. This enables inducible excision of DNA sequences flanked by loxP sites at any age, inactivating a gene of interest. Because ␣-MHC is only expressed in cardiomyocytes and possibly populations of progenitor cells in the myocardium, cardiospecific inactivation of target genes was made possible. This transgene has been used to investigate the role of several proteins important in cardiac function (1, 15, 20) .
MCM is insensitive to estrogen but sensitive to tamoxifen (TAM). The fusion protein is expressed constitutively and retained in the cytosol by binding to the heat shock protein 90 complex (9) . TAM administration leads to conformational changes and redistribution of MCM to the nucleus. Thus administration of TAM leads to Cre recombinase-mediated excision of the DNA sequence that resides between two loxP sites.
Ideally, recombination would be possible without unspecific effects on gene transcription. However, it has been shown that constitutive high levels of Cre recombinase (Cre) not fused to estrogen receptors cause dose-dependent cardiac dysfunction (5). Koitabashi et al. (13) have recently shown that TAM administration to mice expressing the MCM protein (MCM ϩ/0 ) induces an acute cardiomyopathy that was resolved 21 days after the last day of TAM administration. Therefore, at early time points after gene inactivation, there is a potential for confounding interpretation of data obtained from conditional TAM-inducible Cre-loxP mouse models (13) . Also, subsequent to loss of the targeted protein, compensatory changes in the expression of other proteins may occur (1) . The initial cardiomyopathy prohibits investigation of the intended protein loss before such secondary protein changes develop.
The aim of the present study was to develop a protocol that reduced the potentially confounding effects of TAM/MCM. This would allow investigations shortly after gene inactivation within a time frame where the protein of interest is markedly reduced but before compensatory change of transcription of other proteins occurs in cardiomyocytes. A single-injection protocol led to complete and reproducible gene inactivation when applied to cardiomyocyte-specific conditional sarco-(endo)plasmatic reticulum Ca 2ϩ -ATPase2 (Serca2) knockout mice (1), with only minor unspecific transcriptional changes and no detectable acute cardiomyopathy, allowing studies shortly after gene inactivation. We also identified a substantial difference in gene expression between untreated MCM ϩ/0 and wild-type (WT) littermates, which raises important questions regarding proper controls to MCM ϩ/0 with floxed target genes.
METHODS
Animal models. All animals were cared for according to the Norwegian Animal Welfare Act, which conforms to the National Institutes of Health guidelines (NIH publication no. 85-23, revised 1996). Experiments were approved by the Norwegian National Animal Research Committee.
Up to six mice were kept in each cage and housed in a temperatureregulated room with a 12:12-h day-night cycling and had free access to food and water ad libitum.
Mice harboring the MCM transgene under control of the ␣-MHC promoter, Tg(␣MHC-MerCreMer) (MCM ϩ/0 ) (17), were kindly provided by Leon de Windt. Mice were maintained by hemizygous breeding to B6/J mice. Littermates without the MCM gene construct (WT) were used as controls.
Serca2 flox/flox Tg(␣MHC-MerCreMer) mice (MCM ϩ/0 /Serca2 fl/fl ) have previously been described (1, 2) . Administration of TAM, or potentially other specific estrogen receptor modulators, leads to cardiac inactivation of the Serca2 gene in this model. Littermates not encoding MCM (Serca2 fl/fl ) were used as controls. Experimental protocol. TAM free base (T5648; Sigma, Oslo, Norway) dissolved in peanut oil at a concentration of 10 mg/ml was injected intraperitoneally to induce MCM activity in the nucleus. Mice were either treated with TAM injections for four consecutive days at a dosage of 40 mg·kg Ϫ1 ·day Ϫ1 (4d TAM) (Fig. 1, A and B) , as previously described (1), or with a single dosage of 40 mg/kg TAM (1d TAM) (Fig. 1, A and B) . MCM ϩ/0 controls were treated with volume-equivalent injections of peanut oil (0.1 ml).
Mice were anesthetized with isoflurane (1-3%) and killed by cervical dislocation, and the hearts were quickly excised. For RNA microarrays, quantitative RT-PCR (RT-qPCR), and Western blot analyses, left ventricles were immediately frozen in liquid nitrogen (Ϫ80°C). For immunohistochemistry, hearts were frozen in cooled isopentane and stored at Ϫ80°C.
RNA microarray. Total RNA was isolated with an RNeasy mini kit (Qiagen Nordic), and an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) was used to measure RNA quality. An RNA integrity number Ͼ7.5 was required to include samples in further analysis. The total RNA concentration was measured in a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). We used Affymetrix GeneChip Mouse Gene 1.0 ST Array chips (Affymetrix, Santa Clara, CA) containing the 45.101 probe set. Microarray analysis was performed on total RNA from WT 4d TAM, MCM ϩ/0 4d TAM, and MCM ϩ/0 1d TAM, and on corresponding groups of animals treated with control injections (3 animals in each group). RNA microarray analyses were performed 4 days after the first injection of TAM.
Microarray background adjustment was performed using Robust Multichip Average (11) . Significance Analysis of Microarrays (SAM) (19) was used to estimate the fraction of genes altered in one group compared with another group. Pearson's chi squared test was used to evaluate differences in the estimated fractions.
The Database for Annotation, Visualization and Integrated Discovery (DAVID) (6, 10) was used for functional analysis of genes significantly regulated following 1d TAM and 4d TAM. Here a false discovery rate of 0.2 was used as significance cut-off, calculated using SAM.
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (7) and are accessible through GEO Series accession no. GSE19344 (http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?accϭGSE19344).
RT-qPCR. RT-qPCR was performed in MCM ϩ/0 4d TAM and MCM ϩ/0 1d TAM at 1 and 3 days after the last TAM injection for expression of Na ϩ /Ca 2ϩ exchanger (NCX) 1 and L-type Ca-channel (LTCC) ␣1c, and at 4 days after the first TAM injection for expression of ␣-actin-1 and brain natriuretic peptide (BNP). Genetically identical animals treated with corresponding control injections were used as controls. RT-qPCR was also performed on MCM 1d TAM at 0, 1, 2, 4, and 6 days after the first TAM injection. RNA isolation and concentration measurements were the same as for RNA microarray. Reverse transcription was carried out with an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) using 500 ng of template RNA. Expression of mouse Serca2a (Atpa2a, Mm00437634_m1), NCX1 (Scl8a1, Mm00441524_m1), LTCC ␣1c (Cacna1c, Mm00437917_m1), ␣-actin-1 (Acta1, Mm00808218_g1), BNP (Nppb, Mm01255770_g1), and Gapdh (Mm99999915_g1) was quantified using predesigned TaqMan gene expression assays (Applied Biosystems, Foster City, CA) on a 7900HT Fast Real Time PCR System (Applied Biosystems). Samples were amplified in triplicate, and data were analyzed with Sequence Detection Software 2.2.1 (Applied Biosystems). Expression of mRNA was calculated by the relative standard curve method and normalized to Gapdh mRNA.
Western blot analysis. Western blot analyses were performed at 1, 3, and 6 days after the last TAM injection in MCM ϩ/0 4d TAM, MCM ϩ/0 1d TAM, and corresponding groups treated with control injections. Western blot analyses were performed on MCM ϩ/0 / . RT-qPCR was performed at 0, 1, 2, 4, and 6 days after the first injection, and Western analyses and echocardiography were performed 0, 2, 4, and 6 days after the first injection. mRNA microarray analyses in MCM ϩ/0 and WT were performed 4 days after the first injection.
Serca2
fl/fl 4d TAM, Serca2 fl/fl 4d TAM, MCM ϩ/0 /Serca2 fl/fl 1d TAM, and Serca2 fl/fl 1d TAM at 0, 2, 4, and 6 days and 4 and 9 wk after the first TAM injection.
Western blots were performed on total homogenates of the left ventricular samples. Protein concentrations were determined using the bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL) with BSA as standard. Equal amounts of total protein were applied to and separated by standard SDS-PAGE, transferred to polyvinyldifluoride membranes, and blocked with dry milk in Tris-buffered saline with 0.1% Tween 20. The primary antibodies were rabbit anti-NCX-20 (18) , mouse anti-SERCA2A (MA3 919; Affinity Bioreagents, Golden, CO), and rabbit anti-LTCC ␣ 1c (C1603; Sigma). Anti rabbit-or mouse-IgG horseradish peroxidase-linked IgG were used as secondary antibodies (GE Healthcare Amersham Biosciences, Oslo, Norway). Immunoreactive bands were visualized by the enhanced chemiluminescence plus method (GE Healthcare), detected by LAS-1000 or LAS-4000mini (Fujifilm, Stockholm, Sweden), and quantified by ImageQuant software (GE Healthcare).
Immunohistochemistry. Immunohistochemical analyses were performed at 4 wk after TAM injection. Sections (7 m) from frozen hearts were cut on a cryostat (HM 560 MV; Microm International, Walldorf, Germany) at Ϫ18°C, mounted on slides, and air-dried at room temperature. Sections were blocked with 5% BSA (A6003; Sigma) in PBS for 1 h at room temperature, before incubation for 1 h at room temperature with primary antibody [anti-SERCA2a, ab2861 (Abcam, Cambridge, MA), 1:50 dilution in 1% BSA in PBS]. After being washed three times in PBS, the sections were incubated with a secondary antibody [Alexa-488 conjugated IgG, A11017 (Molecular Probes, Eugene, OR), 1:300 dilution in 0.5% BSA in PBS] for 30 min at 37°C and then rinsed three times in PBS. Cover slips were mounted on slides using ProLong Gold antifade reagent (Molecular Probes).
Image analyses were completed using a Zeiss Axioskop 2 (Carl Zeiss Vision, Munich, Germany) microscope fitted with a Zeiss Axiocam (Carl Zeiss) digital camera. Images from five MCM ϩ/0 / Serca2 fl/fl 1d TAM were analyzed; two genetically identical agematched animals not treated with TAM and two Serca2 fl/fl 1d TAM animals were used as controls. The presence of mosaicism was evaluated qualitatively by an individual who was blind to which group each section belonged to. In addition, ImageJ 1.43u software (http:// rsb.info.nih.gov/ij/) was used for semiquantitative analysis of crosssectioned single-cell intracellular fluoresce intensity by measuring the cytosolic mean gray value, avoiding the cell membrane and nucleus; 607 cells from Serca2 fl/fl 1d TAM sections and 381 control cells were examined. Variance between cells in one section was calculated and used as a measurement of variation of SERCA2a levels.
Echocardiography. In vivo cardiac function was assessed in 1d and 4d TAM-treated MCM ϩ/0 /Serca2 fl/fl and Serca2 fl/fl with a fully digitized Vingmed System Five (GE Vingmed Ultrasound, Horten, Norway) equipped with an i13L 13-MHz linear array transducer, as previously described (8), or a Vevo2100 (VisualSonics, Toronto, Canada). Mice were spontaneously breathing, and anesthesia was maintained with ϳ1.75% isoflurane-98.25% oxygen. The identity of each animal was blinded to the investigator (I. Sjaastad). Echocardiography was performed at baseline and day 2, 4, and 6 after the first TAM injection.
Statistics. Numerical data are presented as group means Ϯ SE. Comparisons between groups were done with unpaired Student's t-tests or a two-way ANOVA with a post hoc Student-Newman-Keuls test. Statistics for mRNA microarray are described under mRNA microarray. Differences were considered significant when P Ͻ 0.05. mice were compared with 4d TAM-treated MCM ϩ/0 mice. These experiments showed that 10.9% of the transcriptome was regulated by this treatment (Fig. 2A) . The bioinformatic software DAVID was applied to identify groups of genes in the Gene Ontology (GO) hierarchy (4) enriched with regulated genes. The GO categories with the highest enrichment of regulated genes following 4d TAM were proteosomal genes (enrichment score ϭ 6.6) and cytoskeletal genes (enrichment score ϭ 2.6). Genes significantly regulated following 4d TAM are listed in Supplemental Tables 1 and 2 (Supplemental data for this article may be found in the American Journal of Physiology: Heart and Circulatory Physiology website.).
RESULTS

Both MCM and TAM-MCM interaction induce changes in
The isolated effect of TAM on the transcriptome was investigated to determine whether it was responsible for these changes. Administration of TAM alone altered the expression of 5.6% of the genes (P Ͻ 0.001, Fig. 2B ) in WT treated with 4d TAM compared with control injections. Furthermore, because Cre is known to have effects on gene transcription, we compared differences in gene expression in control injectiontreated MCM ϩ/0 and WT littermates. The microarray data demonstrated that the expression of 35.1% of the genes was significantly different between these two groups (P Ͻ 0.001, Fig. 2C ). This emphasizes the importance of appropriate control groups in Cre-loxP experiments.
Changes in mRNA levels and protein abundance following 4d TAM. Two proteins important for cardiac function were chosen for verification of the mRNA microarray findings in MCM ϩ/0 mice 24 h after completion of the 4d TAM injection protocol. NCX and LTCC ␣1c mRNA levels were downregulated to 26 and 14%, respectively, compared with control injection-treated MCM ϩ/0 (both P Ͻ 0.01, Fig. 3, A and B) . After the last TAM injection (3 days), NCX mRNA expression was increased to 190% of control (P Ͻ 0.01, Fig. 3A) , whereas LTCC ␣ 1c mRNA was only increased to 74% of control (P Ͻ 0.05, Fig. 3B ).
The protein abundance of NCX and LTCC ␣ 1c subunits was investigated by Western blot analysis 24 h, 3 days, and 6 days . B: 4d TAM altered the expression of 5.6% of the examined genes compared with control-injected WT mice. C: constitutive presence of MCM in itself has impact on the gene expression in mice cardiomyocytes. *P Ͻ 0.001 compared with baseline variation in gene expression; **P Ͻ 0.001. after the last TAM injection. At 24 h, NCX protein abundance was reduced to 54% of control levels (P Ͻ 0.01), corresponding to the decline in NCX mRNA. At 3 and 6 days, however, the abundance of NCX protein was similar to control levels [94 and 120% of control, respectively, both not significant (NS), Fig. 3C ]. LTCC ␣ 1c protein abundance was not significantly reduced at 24 h. However, in contrast to NCX, LTCC ␣ 1c was reduced to 47% (P Ͻ 0.01) and 62% (P Ͻ 0.05) 3 and 6 days, respectively, after the fourth injection (Fig. 3D) .
Microarray findings were further verified by measurements of ␣-actin-1 and BNP mRNA levels at the same time point as microarrays were performed. Following 4d TAM, both ␣-actin-1 and BNP mRNA levels were increased when measured by microarray. RT-qPCR verification showed mRNA levels at 726% (P Ͻ 0.01) and 1,302% (P Ͻ 0.05) of control, respectively.
Single-dose TAM protocol minimizes unintended mRNA and protein alterations in MCM ϩ/0 . mRNA microarray analyses were performed on MCM ϩ/0 and WT animals exposed to 1d TAM to determine whether the number of genes with significantly changed expression was lower compared with 4d TAM. Only 2.1% of the genes had altered mRNA levels in 1d TAM-treated MCM ϩ/0 compared with control injection-treated MCM ϩ/0 (P Ͻ 0.001, Fig. 2A ). This is only 1/5 of the number of regulated genes following 4d TAM (P Ͻ 0.001). The GO category with the highest enrichment of regulated genes following 1d TAM was translational genes (enrichment score ϭ 1.3). Genes significantly regulated following 1d TAM are listed in Supplemental Tables 3 and 4 .
With the use of the 1d TAM protocol, NCX and LTCC ␣ 1c mRNA expression, measured by RT-qPCR, was decreased to 39 and 37% of control levels (both P Ͻ 0.01) 24 h after the injection. After the single injection (3 days), the mRNA levels of NCX and LTCC ␣ 1c were restored to control levels (113 and 101%, respectively, NS, Fig. 3, A and B) , and there was no significant alteration in protein abundance for NCX or LTCC ␣ 1c at these time points (Fig. 3, C and D) .
After a single injection (4 days), microarray measurements did not show significant changes of ␣-actin-1 nor BNP mRNA levels. RT-qPCR showed an ␣-actin-1 mRNA level at 46% of control (NS), and the BNP mRNA level was 177% of control (P Ͻ 0.01), thus substantially less alteration than following 4d TAM. (Fig. 4, A and C) , left ventricular fractional shortening was reduced at 4 and 6 days compared with baseline at 0 days (37 and 45%, respectively, both P Ͻ 0.001, Fig. 4, B and C) . However, a significant change in neither left ventricular diastolic diameter nor fractional shortening was observed after the 1d TAM protocol (Fig. 4) .
A single dose of TAM does not induce acute cardiomyopathy in MCM
The finding of normal in vivo function following 1d TAM was supported by unaltered NCX mRNA levels and protein abundance. The first day after the 1d TAM injection, NCX mRNA levels in MCM ϩ/0 /Serca2 fl/fl followed the same pattern as following 4d TAM and decreased by ϳ50% compared with baseline. However, the NCX mRNA level returned to baseline levels from day 2 using the 1d TAM protocol, whereas it was suppressed until day 4 using the 4d TAM protocol (Fig. 5A) . NCX protein abundance was nominally 10 -23% above baseline at all three time points following the 1d TAM protocol but significantly increased only at day 4 (Fig. 5B) . NCX protein abundance was reduced to 61 Ϯ 9% (P Ͻ 0.01) 4 days after the first TAM injection following the 4d TAM protocol (Fig. 5B ) and increased to 167 Ϯ 30% (P ϭ 0.06) of baseline levels at day 6 (Fig. 5B) .
Single-dose TAM is sufficient to induce gene disruption in MCM
ϩ/0 /Serca2 fl/fl mice. The gene inactivation efficacy of 4d TAM and 1d TAM were evaluated in this model by the reduction in Serca2 mRNA 1, 2, 4, and 6 days after the first TAM injection, and by intraindividual homogeneity of SERCA2a loss. Serca2 mRNA levels following 4d and 1d TAM followed the same pattern, and, although there were statistically significant differences between the two protocols (Fig. 6A) , these differ- ences probably are too small to be biologically significant. SERCA2a protein abundance actually declined faster following 1d TAM than 4d TAM, which is opposite to the decline rate of mRNA (Fig. 6B ). Serca2a mRNA levels and SERCA2 protein both declined as previously reported with a protein half-life of 2-3 days (1). After a single TAM injection (4 wk), loss of SERCA2, evaluated by a blinded investigator, was homogenous in sections from all hearts investigated, i.e., no mosaicism was found. Indeed, the intraindividual variance of fluorescence intensity measured in 607 cells from 10 MCM ϩ/0 /Serca2 fl/fl sections and 381 cells from 8 control sections was lower among MCM ϩ/0 /Serca2 fl/fl animals than controls (1.8 vs. 5.0 arbitrary units, Fig. 6E ). To verify a persistent reduction in SERCA2a level, the long-term reduction in SERCA2a was investigated at 4 and 9 wk after gene inactivation. At these time points, SERCA2a protein abundance was Ͻ2.5% in 1d TAM (Fig. 6C) , not different from the SERCA2a level at 7 wk after the 4d TAM (1). Therefore, 1d TAM is sufficient for inducing complete inactivation of the Serca2 gene in MCM ϩ/0 /Serca2 fl/fl mice.
DISCUSSION
We demonstrate that the extensive change in gene expression, protein abundance, and acute cardiomyopathy after the 4d TAM protocol is avoided by using the 1d TAM protocol. The 1d TAM protocol also gave near-total myocardial inactivation of the Serca2 gene in an MCM ϩ/0 /Serca2 fl/fl model, with protein abundance below the detection limit at 9 wk. The single injection protocol thus allows studies shortly after disruption of transcription and also within a time frame before any major cellular compensation due to reduced target abundance level occurs. Interestingly, we also observed major differences in gene expression in untreated MCM ϩ/0 compared with WT. This has, to our knowledge, not been reported previously and raises important questions regarding the choice of controls to TAMtreated MCM ϩ/0 . In previous studies, both floxed mice without the MCM transgene (1, 15) and nonfloxed MCM ϩ/0 (20) have been used as controls, as well as floxed MCM ϩ/0 treated with TAM vehicle as control injections (20) . Because there are major baseline differences in gene expression between animals with and without the MCM genotype, mice not encoding MCM might not be sufficient as the only control. Also, we only observed a minor effect of TAM on gene regulation using 4d TAM in WT and would expected even fewer regulated genes using 1d TAM. The fact that TAM has an effect on the transcriptome suggests that nonfloxed MCM ϩ/0 treated with TAM are appropriately included as controls to floxed MCM ϩ/0 mice.
We did not investigate the mechanism for the cardiomyopathy, but it is possible that, in addition to direct effects on the cardiomyocytes due to TAM/MCM, indirect effects through potential ␣-MHC-expressing progenitor cells in the myocardium may be partly responsible for the cardiomyopathy. Pre- vious studies have shown high cardiospecific Cre expression to be cardiotoxic (5, 14, 16) . Similar to the study by Koitabashi et al. (13) , we found that the in vivo cardiac dysfunction induced by the 4d TAM protocol in MCM ϩ/0 was transient, with nearly normalized function after 12 days (data not shown). We speculate that the severe and transient cardiomyopathy might influence the phenotype at later time points after gene disruption, making short TAM exposure protocols preferable.
The 1d TAM was also followed by significant changes in gene expression in MCM ϩ/0 , but the changes were smaller and shorter lasting than following 4d TAM. mRNA levels quickly returned to baseline within 24 -48 h. A major advantage of 1d TAM was the negligible functional impact of the changes in mRNA levels suggested by the absence of detectable alterations in protein abundance. With the use of the 1d TAM protocol, the transient cardiomyopathy seen in response to the 4d TAM protocol was avoided.
Also, 1d TAM gave a rapid decline in mRNA expression from the targeted gene with low interindividual variation and a corresponding decline in protein abundance during the first week, compatible with a complete gene inactivation as seen with the 4d TAM protocol. This allows investigation of acute protein loss only a few days following gene inactivation using the 1d TAM protocol.
Oral administration of TAM in the chow may also be used for gene disruption in models using the MCM transgene (3, 12) and is shown to lead to complete recombination in cardiomyocytes (3). A limitation of administrating TAM to the animal through chow is the uncertainty regarding the amount of food consumed by each individual. Kiermayer et al. (12) suggests that mice transiently refuse TAM containing chow. Also, individual differences in food intake probably lead to heterogeneous levels of TAM in the tissues not only during the first days of drug administration but also later during long protocols (12) . Thus an important aspect to consider using oral administration protocols is that the variability in TAM uptake will give variable mRNA levels and protein abundance shortly after induction of gene inactivation, although this could depend on the type of chow (3). Also, feeding will give longer TAM exposure than a single injection. Accordingly, a single injection of TAM, when applicable, might be preferred to per oral feeding protocols when studying functional effects early after gene inactivation.
Other selective estrogen receptor modulators may be an alternative to TAM. Koitabashi et al. (13) showed that raloxifen (160 mg/kg per oral raloxifen for 21 days) did induce adequate gene inactivation without negative effects on cardiac function 1 wk after completion of the protocol (13) . Raloxifen, however, is poorly soluble, and the doses necessary for efficient gene disruption by intraperitoneal injections would require too large volumes for administration to mice (13) . Raloxifen would therefore be unsuitable for short-term parenteral administration.
We have managed to avoid the problem with unintended changes following 4d TAM administration by using a single injection protocol. The extensive alteration of the transcriptome seen with 4d TAM in MCM ϩ/0 was reduced to 1/5, the protein abundance was preserved, and the acute cardiomyopathy seen in MCM ϩ/0 /Serca2 fl/fl was avoided. Applied to the MCM ϩ/0 /Serca2 fl/fl , the single-injection protocol resulted in the same pattern of mRNA decline as with the longer protocol, both reaching minimal levels of mRNA 6 days after the start of the protocol. Also, the SERCA2a protein was still not detectable 9 wk after gene inactivation following 1d TAM.
We suggest that other cardiospecific transgenic mouse models encoding MCM also could be sensitive to sustained exposure to TAM. Accordingly, the efficacy and side effects of the protocol have to be evaluated for all similar genetically engineered systems, and intended controls have to be validated. However, the optimal dose and exposure time of TAM to obtain complete gene disruption might vary, e.g., due to the level of MCM protein expressed in each strain or the accessibility of the floxed locus. The protocol of DNA recombination should, as also pointed out by Koitabashi et al. (13) , be thoroughly investigated in every model with respect to adverse effects and efficacy of target gene inactivation.
In conclusion, MCM ϩ/0 mice have a high number of regulated genes compared with their WT littermates, emphasizing the importance of appropriate controls in studies with TAMdependent Cre-induced inactivation of genes. Furthermore, a single dose of 40 mg/kg ip TAM is sufficient to induce gene inactivation in MCM ϩ/o /Serca2 fl/fl without inducing acute cardiomyopathy, allowing studies of the acute effects of isolated protein reduction. This single-injection protocol might be applied to other transgenic mouse models based on Cre-loxP DNA recombination to optimize gene inactivation.
